Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.
Beyond the well-known mRNA vaccines for COVID-19, therapeutic RNAs are emerging in diverse medical fields, including cardiology, ophthalmology, infectious diseases, and hepatology. However, could they also hold promise in rheumatology?, PhD, from the Centre Hospitalier Universitaire de Montpellier, Montpellier, France , affirmed their potential, describing these small genetic molecules as “a promising solution in rheumatology.
Apparailly focused on advances in rheumatology research on small noncoding RNAs during her presentation. “Their big advantage is that it is possible to synthesize any sequence in very large quantities, in a short time and for a much more competitive price than traditional small molecules,” she said.Antisense oligonucleotides have been evaluated in rheumatoid arthritis and systemic lupus erythematosus to modulate the immune system activity and reduce the inflammatory response.
Rheumatoid Arthritis (RA) Lupus Systemic Lupus Erythematosus Systemic Lupus Erythaematosus SLE Systemic Lupus Erythematosus (SLE) Genomics Genomic Medicine Arthritis Joint Inflammation France French Biologic Therapy Biologics DNA Sequencing DNA Sequence DNA Sequences Sequencing DNA Next-Generation Sequencing NGS Sequencing By Synthesis SBS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 BillionJohnson & Johnson unveils a major acquisition, purchasing Intra-Cellular Therapies for $14.6 billion to bolster its central nervous system disorder treatment portfolio. The deal focuses on Caplyta, a promising drug for schizophrenia and depression, with strong anticipated growth.
Read more »
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 BillionJohnson & Johnson (J&J) is acquiring Intra-Cellular Therapies for over $14 billion, marking a significant investment in the treatment of central nervous system disorders. The deal includes a premium payment of $132 per share for Intra-Cellular, granting J&J ownership of Caplyta, a promising drug for schizophrenia and bipolar depression. J&J intends to leverage Intra-Cellular's pipeline, which includes potential treatments for anxiety, psychosis, and Alzheimer's-related agitation, to bolster its presence in this growing market.
Read more »
Postdoctoral Research Associate Position: Uncovering the Role of RNA in Cancer GenomesThe Cupido Laboratory at St. Jude Children's Research Hospital seeks a postdoctoral research associate to investigate the role of RNA-based processes in shaping cancer genomes. The position will focus on uncovering the molecular links between RNA-based machinery functions and gene transcription regulation using cutting-edge techniques.
Read more »
Novel Bone Remodeling Factor Fam102a Identified: Potential for Osteoporosis TherapiesResearchers at the Faculty of Dentistry, Institute of Science Tokyo, have discovered the protein Fam102a as a novel regulator of bone remodeling. Fam102a influences the differentiation of both osteoclasts (bone-resorbing cells) and osteoblasts (bone-forming cells), playing a crucial role in maintaining bone health. The study, published in [Journal Name], reveals the protein's involvement in the nuclear trafficking of key transcription factors, impacting bone formation and resorption. This discovery opens new avenues for developing innovative therapeutic strategies to combat osteoporosis.
Read more »
Vita Health Group Wins NHS Talking Therapies Contract in DerbyshireVita Health Group will take over providing NHS talking therapy services in Derbyshire after the current provider withdrew due to budget concerns. The contract transfer is expected to affect around 78 staff. While the service will remain free at the point of need, concerns have been raised by MPs and unions about potential impacts on patient access and service quality.
Read more »
Promise for CAR T-Cell Therapies in Solid Tumors?CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in targeting solid tumors have been limited.
Read more »